摘要
目的：肾移植病人服用环孢霉素A易诱发高血压症和产生肾毒性。钙通道阻滞剂对移植术后高血压症有良好的降压作用。本实验，我们研究尼卡地平用于肾移植病人的长期疗效。方法：41例肾移植病人随机分为二组：尼卡地平为治疗组；硝苯地平为对照组。进行长达二年以上的临床观察。两组病人年龄、性别、体重、临床指征无显著差异。结果：显示尼卡地平干扰环孢霉素A(CsA)代谢，导致CsA剂量降低30%，但未见其增强CsA肾毒性。结论：本实验结果提示尼卡地平用于肾移植并发高血压症病人安全有效，并能节约肾移植病人的费用。
OBJECTIVE: Hypertension and nephrotoxicity are frequent in renal transplant patients treated with cyclosporine. Calcium-channel blockers have been shown to be efficient in controlling postoperative hypertension. In this report, we studied the results of the long-term use of nicardipine after renal transplanation. METHODS: Forty-one transplant patients with a follow-up longer than 2 years were studied. Patients were divided into two groups at random: ①treated with nicardipine group;②treated with nifedipine group. The two groups were similar for age, sex, body weight and transplanation indications. RESULTS: The results showed that nicardipine interacts with CsA metabolism, leading to a 30% reduction in CsA dose and does not increase the risk of CsA toxicity or graft rejection. CONCLUSIONS: The data suggest that nicardipine can be used safely for the treatment of hypertension after renal transplanation with potential cost savings.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2000年第5期342-344,共3页
The Chinese Journal of Clinical Pharmacology
